1. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez Cet al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 2021; 384(7):619-629.
2. Mazurskaya PZ. Organization of receptive fields in the forebrain of Emys orbicularis. Neurosci Behav Physiol 1973; 6(4):311-318.
3. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa Met al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179 Suppl 1:S18-23.
4. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20(4):398-400.
5. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson Let al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin Infect Dis 2015; 61(4):496-502.
6. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize Set al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016; 374(1):33-42.
7. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357(14):1450-1451.
8. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WWet al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52(4):447-456.
9. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MHet al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24(1):44-46.
10. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WSet al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211(1):80-90.
11. Zhao JY YJ, Qu JM. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl) 2020; 133(9):1087-1095.
12. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1):58-60.
13. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 2020; 178:104791.
14. Naydenova K, Muir KW, Wu LF, Zhang Z, Coscia F, Peet MJet al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc Natl Acad Sci U S A 2021; 118(7):2021946118.
15. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia Jet al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020.
16. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari Aet al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 2015; 4:709.
17. Duan K, Liu B, Li C, Zhang H, Yu T, Qu Jet al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117(17):9490-9496.
18. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan Jet al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020.
19. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Yet al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223):507-513.
20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Yet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497-506.